An API & CDMO Company
Glochem Industries
Excellence in every Molecule we develop in R&D & manufacture in Plant
Table of Contents
1
Home
Philosophy, Group of Companies, Manufacturing Overview, Global Presence
2
About Us
Company Story, Leadership Team, Certifications
3
Our Products
API Commercial, Products Under Development, Intermediates & KSMs, Speciality Chemicals
4
Research & Facilities
World Class R&D, API R&D, CDMO R&D, Core Chemistry, IP Management
5
Manufacturing
API/CRAMS Capability, Group of Companies, Capabilities Detail, Equipment Tables
6
Sustainability
Approach, Climate Action, Safety Excellence, Governance Framework, Impact
7
ESG
ESG Profile, Recognitions, Low Carbon Model, OHS Actions, Milestones
8
Get In Touch
Communication Channels, Office Network
Page 1 of 8
1
Home
Glochem Industries is an API & CDMO company with dedicated manufacturing site for CDMO & API, committed to excellence in every molecule — driven by science and designed for the future.
Our Philosophy: FIT FOR FUTURE
Safety First, Quality Always, Productivity Daily
Glochem operates at the intersection of pharmaceutical APIs, CDMO solutions, and specialty chemicals — pooling and creating efficiencies across sectors. The company is a Proud Member of the UN Global Compact (UNGC).
Group of Companies
Specialized subsidiaries driving innovation across pharmaceutical sectors:
CHIERON
High quality generic API (with key markets: US, Europe, Japan, Korea & Brazil). End-to-end CDMO Solutions for complex molecules and KSMs, from development to commercial marketing. High Purity material for Semi-Conductors, OLED & Speciality Chemicals.
chieron.com
chieron.com
MAKSONS
Dedicated CDMO units for Intermediates, Speciality Chemicals & OLED. Advanced specialty chemicals for high-performance applications, driven by precision, customization, and scalable manufacturing.
maksons.com
maksons.com
Manufacturing Capabilities (Summary)
| Particulars | Chieron | Glochem | Maksons |
|---|---|---|---|
| Total Reactors | 41 | 46 | 13 |
| Dryers | 10 | 16 | 02 |
| Reactors – SSR | 38 | 38 | 10 |
| Reactors – GLR | 21 | 8 | 03 |
| Size Reduction Equipment | 07 | 12 | 01 |
Global Presence Network
Glochem maintains a strong sales presence across international markets including US, Europe, Japan, Korea, Brazil, and emerging markets.
Our Office Network
Hyderabad (Corporate)
3rd Floor, NCC Building, Vital Rao Nagar Colony, Hyderabad 500 081
Ahmedabad
Plot No. C-10, Akshar Industrial Park, Opp. Zydus Life Sciences, Changodar - 382213, Gujarat
Mumbai
20th Floor, Tower 2, Unit No. 2001, One International Center, Senapati Bapat Marg, Mumbai - 400 013
Bangalore
91 Springboard, Bannerghatta Rd, Dollars Colony, Phase 4, J. P. Nagar, Bengaluru 560076
Page 2 of 8
2
About Us – The Glochem Legacy
Excellence in every Molecule we develop in R&D & manufacture in Plant
Our Story
2026
- Glochem acquired Maksons Fine Chem Pvt Ltd in Mar 2026
2025
- Glochem acquired Chieron Active Ingredients Pvt Ltd in Feb 2025
- Successfully completed PMDA audit in May 2025
- Inception of a new R&D facility in Ahmedabad
- Successful WHO GMP audit in July 2025 and USFDA in 2024
- Chieron – Ecovadis Gold Certification
- Glochem – Ecovadis Silver Certification
2024
- CEP approval received for 2 APIs
- ECOVADIS certification achieved
- Awarded the Golden Peacock for sustainability
- Applied for PSCI membership
- Achieved B rating in CDP
2023
- China approval – Received 'A' status for 4 APIs
- First filing in CADIFA, Brazil – Olmesartan
2020
- State-of-the-art production block-2 inaugurated
2017–2019
- USFDA site approval I & II
2016
- Achieved zero liquid discharge (ZLD) milestone
2015
- EDQM approval obtained
2011
- KFDA approval obtained
2010
- WHO GMP & ISO-9001 certified
2008–2009
- First Drug Master Files (DMFs) filed globally
2007
- Start of commercial manufacturing operations
Core Values
TRUSTED
by global regulators & customers
INNOVATIVE
portfolio expansion
COMMITMENT
to safety, quality & excellence
Workup & Isolation
Advanced equipment for downstream operations like Sparkler filter, ANF & ANFD etc.
High-vacuum distillation and VTD systems
CGMP-compliant purification for heat-sensitive and viscous intermediates
Management Team
Visionary leadership driving scientific excellence and global operations
Mr. Chandra Kumar Verma
MD & Chief Executive Officer
Visionary business leader with over two decades of experience across global APIs, intermediates, and formulations. Holds a B.E. in Chemical Engineering and a PGDM in Marketing & Operations. Successfully scaled businesses to revenues exceeding USD 200 million. Led multiple M&A transactions; launched over 300 APIs and 50 FDFs across regulated and emerging markets.
Mr. Bodhisatwa Ray
Chief Finance Officer
Seasoned finance leader with over 20 years of global experience. Chartered Accountant and alumnus of IIM Ahmedabad. Spent over a decade at Pfizer leading finance, taxation, treasury, and M&A. Has held leadership roles at Dr. Reddy's Laboratories and HSBC. Focuses on financial governance, transparency, and value creation.
Mr. Naga Seshaiah Kalki
Chief Operating Officer
Operations leader with 35+ years of experience across sterile and non-sterile APIs and Injectable dosage forms. Proven track record in leading large-scale manufacturing operations, delivering greenfield and brownfield projects, and successfully navigating USFDA and international regulatory audits. Worked with Lupin, Orchid Pharma, Ranbaxy, Hospira, Biocon. Graduate in Pharmacy with a PGDIM.
Dr. Swarup Datta
Head – R&D (CDMO)
Pharmaceutical R&D leader with two decades of experience. Held leadership roles at Piramal Pharma, Aragen Life Sciences, Glenmark Life Sciences, Syngene International, and Daiichi Sankyo India Pharma. PhD in Organic Chemistry from National Tsing Hua University, Taiwan; postdoctoral experience from University of Saarland, Germany, and University of Oxford, UK.
Dr. Kirti Prakash Jain
Head – R&D (API)
R&D executive with over 24 years of distinguished leadership in Active Pharmaceutical Ingredient (API) research, process development, and commercial manufacturing. Held pivotal R&D leadership roles at Sun Pharma, Ipca Laboratories, Hikal, Ami Life Sciences, Cadila Pharmaceuticals, and Ranbaxy Laboratories. Leads the organization's R&D center in Ahmedabad, driving end-to-end API strategy, flow chemistry, process intensification, and green technologies. Holds M.Sc. and Ph.D. in Chemistry with credit for over 25 patented technologies.
Mr. T. G. Vinod
Chief Supply Chain Officer
Seasoned supply chain leader with over 25 years of pharmaceutical industry experience. Held leadership roles at Dr. Reddy's Laboratories and ZCL Chemicals. Managed procurement spends exceeding USD 100 million. Built resilient supplier networks across India and China.
Venkat "Srini" Srinivas
Chief Information Officer
Transformational technology leader with over 25 years of global experience driving digital innovation across the pharmaceutical and life sciences industries. Prior senior executive roles at Apotex and Cohance Lifesciences. Holds a B.E. in Computer Science and an MBA with executive education from NMIMS.
Niraj Agrawal
Chief Human Resources Officer
Strategic HR leader with over three decades of experience shaping organizations. Led HR agendas at Dr. Reddy's Laboratories, Wockhardt, HVAL (Tata Enterprise), Essel Mining (Aditya Birla Group), and Deepak Fertilisers. Holds a PG Diploma in Personnel Management from XISS, Ranchi.
Certifications
Accredited by leading international quality, environmental, and safety organizations:
PSCIEcovadisCDPScience Based TargetsGRIBritish Safety CouncilUN Global Compact
Page 3 of 8
3
Our Products
FIT FOR FUTURE through Sustainable Excellence
API Commercial (26 Products)
| S.No | API | USDMF | CEP | JDMF | KDMF | CADIFA | CDMF | Therapeutic Use |
|---|---|---|---|---|---|---|---|---|
| 1 | AIPAU | -- | -- | √ | √ | -- | -- | Analgesic |
| 2 | Benfotiamine | -- | -- | -- | -- | -- | -- | Vitamin Supplement |
| 3 | Dapagliflozin Propanediol | √ | √ | -- | -- | -- | -- | Anti Diabetic |
| 4 | Lacosamide | √ | √ | √ | √ | √ | A Status | Anti Convulsant |
| 5 | Levetiracetam | √ | √ | √ | √ | √ | A Status | Anti Convulsant |
| 6 | Linagliptin | √ | EDMF | -- | -- | √ | √ | Anti Diabetic |
| 7 | Loxoprofen Acid / Sodium | -- | -- | -- | -- | -- | -- | Anti Inflammation |
| 8 | Olmesartan Medoxomil | √ | √ | √ | √ | √ | √ | Anti Hypertensive |
| 9 | Oseltamavir Phosphate | -- | -- | -- | -- | -- | * | Anti viral |
| 10 | Quetiapine Fumarate | -- | -- | -- | -- | -- | -- | Anti Psychotic |
| 11 | Risperidone | √ | √ | -- | √ | √ | √ | Anti Psychotic |
| 12 | Rivaroxaban | √ | * | -- | -- | -- | -- | Anticoagulant |
| 13 | Sitagliptin Phosphate (Chemical) | √ | * | -- | -- | -- | -- | Anti Diabetic |
| 14 | Sitagliptin Phosphate (Enzymatic) | √ | * | -- | -- | -- | -- | Anti Diabetic |
| 15 | Tetracaine Base/ HCL | √ | √ | -- | -- | √ | A Status | Anaesthetic |
| 16 | Vildagliptin | √ | -- | -- | -- | -- | -- | Anti Diabetic |
| 17 | Warfarin S Amorphous | √ | √ | -- | -- | -- | * | Coagulant |
| 18 | Warfarin S Clathrate | √ | √ | -- | -- | -- | √ | Anti Coagulant |
| 19 | Amlodipine Besylate | √ | √ | √ | √ | √ | √ | Anti Hypertensive |
| 20 | S(-) Amlodipine Besylate | √ | -- | -- | √ | √ | -- | Anti Hypertensive |
| 21 | Amlodipine Maleate | -- | -- | -- | -- | Status | -- | Anti Hypertensive |
| 22 | Cetirizine Dihydrochloride | √ | -- | -- | √ | A Status | √ | Anti Histaminic |
| 23 | Levocetirizine Dihydrochloride | √ | √ | √ | √ | √ | √ | Anti Histamines |
| 24 | Hydroxyzine Hydrochloride | √ | √ | -- | -- | √ | √ | Anti Histaminic |
| 25 | Raloxifene Hydrochloride | √ | √ | -- | -- | -- | -- | Anti Osteoporotic |
| 26 | Telmisartan | √ | √ | -- | -- | -- | -- | Anti Hypertensive |
Products Under Development
| Product 1 | Product 2 | Product 3 |
|---|---|---|
| Azilsartan Medoxomil Potassium | Eprazinone dihydrochloride | Ezetimibe |
| Methylphenidate | Nebivolol hydrochloride | Pelubiprofen |
| Tegoprazan | Vonoprazan Fumarate | Zonisamide |
| Bilastine | Famotidine | Lercanidipine |
API – Under Evaluation
| Product Name | ||
|---|---|---|
| Risdiplam | Tegoprazan | Pelubiprofen |
| Acoramidis | Isavuconazole | Fosravuconazole |
| Fluvoxamine Maleate | Fenfluramine | Vilanterol |
| Retagliptin | Elafibranor | Anagliptin |
| Nafamostat | Sotagliflozin | Lumateperone |
| Levothyroxine Sodium | Tolvaptan | Rebamipide |
| Letermovir | Finerenone | Roxadustat |
| Mavacamten | Eprazinone | Ipragliflozin |
| Opicapone | Dorzagliatin | |
Intermediates & KSMs (35 items)
| S.No | Product / Intermediate | CAS No. | End Product |
|---|---|---|---|
| 1 | Amlodipine Phthalimido / Base | 88150-62-3, 88150-42-9 | Amlodipine |
| 2 | 4-(hydroxymethyl)-5-methyl-1,3-dioxol-2-one | 91526-18-0 | Azilsartan medoxomil |
| 3 | Methyl 1-[(2'-Cyano-[1,1'-biphenyl]-4-yl)methyl]-2-ethoxy-1H-benzo[d]imidazole-7-carboxylate | 139481-44-0 | Azilsartan medoxomil |
| 4 | Methyl 2-ethoxy-1-((2'-(N-hydroxycarbamimidoyl)-[1,1'-biphenyl]-4-yl)methyl)-1H-benzo[d]imidazole-7-carboxylate | 147403-65-4 | Azilsartan medoxomil |
| 5 | Methyl 2-Ethoxy-1-[[2'-(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl) biphenyl-4-yl]methyl]benzimidazole-7-carboxylate | 147403-52-9 | Azilsartan medoxomil |
| 6 | Azilsartan (2-Ethoxy-1-[[2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylic acid) | 147403-03-0 | Azilsartan medoxomil |
| 7 | 8-bromo-7-(but-2-ynyl)-3-methyl-1H-purine-2,6(3H,7H)-dione (LG-1) | 666816-98-4 | Linagliptin |
| 8 | 2-(4-(bromomethyl)phenyl) propanoic acid (BPP) | 111128-12-2 | Loxoprofen |
| 9 | Methyl Cyclopentanone-2-carboxylate (MCP) | 10472-24-9 | Loxoprofen |
| 10 | 2-Phenyl-2-(Pyridine-2-yl)acetamide (PPA) | 7251-52-7 | Methylphenidate |
| 11 | Ritinalic Acid** | 19395-41-6 | Methylphenidate |
| 12 | 2-Phenyl-2-(Piperidine-2-yl) acetamide (Mixture of Diastereomers) | 19395-39-2 | Methylphenidate |
| 13 | 6-Fluoro-3,4-Dihydro-2H-benzopyran-2-Carboxylic acid | 99199-60-7 | Nebivolol HCl |
| 14 | (±)-[R*(R*)]-6-Fluoro-3,4-Dihydro-2-Oxiranyl-2H-1-Benzopyran | 876514-31-7 | Nebivolol HCl |
| 15 | (±)-[1S*(R*)]-6-Fluoro-3,4-Dihydro-2-Oxiranyl-2H-1-Benzopyran | 793669-26-8 | Nebivolol HCl |
| 16 | rac N-Benzyl Nebivolol // BENL | 929706-85-4 | Nebivolol HCl |
| 17 | Trityl Olmesartan Medoxomil | 144690-92-6 | Olmesartan |
| 18 | Ethyl 4-(1-hydroxyl-1-methylethyl)-2-propyl-imidazole-5-carboxylate | 144689-93-0 | Olmesartan |
| 19 | (1S,5R,6S)-Ethyl 5-(pentan-3-yloxy)-7-oxa bicyclo[4.1.0]hept-3-ene-3-carboxylate | 204254-96-6 | Oseltamivir |
| 20 | 4-CHLOROMETHYL-5-METHYL-1,3-DIOXOL-2-ONE (DMCO CI) | 80841-78-7 | Olmesartan |
| 21 | Ethyl (3R,4R,5S)-4-(N-tert-butylacetamido)-5-(diallylamino)-3-(pentan-3-yloxy)-cyclohex-1-enecarboxylate hydrochloride | 651324-08-2 | Oseltamivir |
| 22 | Dibenzo[b,f] thiazepine-11(10H)-one | 3159-07-7 | Quetiapine Fumarate |
| 23 | 1-[2-(2-Hydroxyethoxy)ethyl]Piperazine | 13349-82-1 | Quetiapine Fumarate |
| 24 | (R)-5-Chloro-N-(2-hydroxy-3-((4-(3-oxo morpholino)phenyl)amino)propyl)thiophene-2-carboxamide | 721401-53-2 | Rivaroxaban |
| 25 | 1-(3-(Trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)-4-(2,4,5-trifluorophenyl)butane-1,3-dione | 764667-65-4 | Sitagliptin |
| 26 | 2-(2,4,5-trifluorophenyl)acetic acid | 209995-38-0 | Sitagliptin |
| 27 | 3-(trifluoromethyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazine hydrochloride | 762240-92-6 | Sitagliptin |
| 28 | 4-[[((4S)-5,7-difluoro-3,4-dihydro-2H-1-benzopyran-4-yl)oxy]-N,N,2-trimethyl-1-[(4-methylphenyl)sulfonyl]-1H-benzimidazole-6-carboxamide] | 942485-42-9 | Tegoprazan |
| 29 | (4S)-5,7-difluoro-3,4-dihydro-2H-1-benzopyran-4-ol | 942195-91-7 | Tegoprazan |
| 30 | 4-hydroxy-N,N,2-trimethyl-1-[(4-methylphenyl)sulfonyl]-1H-benzimidazole-6-carboxamide | 942195-86-0 | Tegoprazan |
| 31 | N,N,2-trimethyl-1-[(4-methylphenyl)sulfonyl]-4-(phenylmethoxy)-1H-benzimidazole-6-carboxamide | 942195-85-9 | Tegoprazan |
| 32 | 5-(2-Fluorophenyl)-1H-pyrrole-3-carboxaldehyde | 881674-56-2 | Vonoprazan Fumarate |
| 33 | 5-(2-Fluorophenyl)-1-[(pyridin-3-yl)sulfonyl]-1H-pyrrole-3-carboxaldehyde | 881677-11-8 | Vonoprazan Fumarate |
| 34 | Ethyl 5-(2-fluorophenyl)-1H-pyrrole-3-carboxylate | 881674-06-2 | Vonoprazan Fumarate |
| 35 | (S)-2-Methylpyrrolidine-2-carboxylic acid | 1508261-86-6 | Daridorexant Hydrochloride |
Speciality Chemicals – OLED, Semiconductor & Contrast Media (25 items)
| S.No | Chemical Name | CAS No. | End Use |
|---|---|---|---|
| 1 | Iohexol | 66108-95-0 | Contrast Media |
| 2 | 4-Chloro-2-iodoaniline | 63069-48-7 | Contrast Media |
| 3 | 5-Nitro Isophthalic acid | 618-88-2 | Contrast Media |
| 4 | Iopamidol | 60166-93-0 | Contrast Media |
| 5 | 5-Iodo-2-methylbenzoic acid | 54811-38-0 | Contrast Media |
| 6 | 1,4,7,10-Tetraazacyclo dodecane | 294-90-6 | Contrast Media |
| 7 | 10-(2-Hydroxypropyl)-1,4,7,10-tetraaza cyclododecane-1,4,7-triacetic acid | 120041-08-9 | Contrast Media |
| 8 | 5-Amino-N,N'-bis(2,3-dihydroxypropyl) isophthalamide Hydrochloride | 203515-86-0 | Iohexol / Contrast Media |
| 9 | Dimethyl-5-Nitroisophthalate | 13290-96-5 | Iohexol / Contrast media |
| 10 | 5-Amino-2,4,6-Triiodoisophthaloyl Dichloride | 37441-29-5 | Iohexol / Contrast media |
| 11 | 5-Amino-2,4,6-Triiodoisophthalic Acid | 35453-19-1 | Iohexol / Contrast media |
| 12 | N-(1-Methylpropyl)-4-[(1-methylpropyl)imino]-2-penten-2-amine | 917952-30-8 | Semiconductor |
| 13 | 1,1'-methylene bis (N,N,N,1-tetramethyl silanamine) | 86053-30-7 | Semiconductor |
| 14 | 2,2,4-Trimethyl-2,4-Disilapentane | 1189-75-9 | Semiconductor |
| 15 | 1-(1-Methylethyl)cyclohexyl 2-methyl-2-propenoate (IPCHMA) | 811440-77-4 | Semiconductor |
| 16 | 2-methyl-2-[(hexahydro-2-oxo-3,5-methano-2H-cyclopenta[b]furan-6-yl)oxy]-2-oxoethyl ester, 2-Propenoic acid (ACNLM) | 347886-81-1 | Semiconductor |
| 17 | 2-Ethyl-2-adamantyl methacrylate (EAdMA) | 209982-56-9 | Semiconductor |
| 18 | 2-Methylacrylic Acid 2-Oxotetrahydrofuran-3-yl Ester | 195000-66-9 | Semiconductor |
| 19 | 1-Methyl-1-cyclopentyl Methacrylate (McPMA) | 178889-45-7 | Semiconductor |
| 20 | 2-Methyl-2-adamantyl methacrylate (MAdMA) | 177080-67-0 | Semiconductor |
| 21 | 3-Hydroxy-1-methacryloyl oxyadamantane (HMA) | 115372-36-6 | Semiconductor |
| 22 | 1-(1-methylethyl)cyclopentyl 2-methyl-2-propenoate (IPCPMA) | 1149760-04-2 | Semiconductor |
| 23 | 2-Iodobenzoic acid | 88-67-5 | Specialty Chemicals |
| 24 | Diiodomethane | 75-11-6 | Specialty Chemicals |
| 25 | 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide Hydrochloride (EDC-HCl) | 25952-53-8 | Specialty Chemicals |
Page 4 of 8
4
Research & Facilities
Innovation Through Integration — Building R&D Capabilities FIT FOR FUTURE
World Class R&D Capabilities
Our R&D department leverages scientific expertise and scalable design to drive IP-focused innovation. Through rigorous regulatory standards and collaborative engineering, we provide the global market with high-quality, cost-efficient APIs.
- Scientific, diversified & technical expert team
- Ability to design robust, reproducible, and scalable synthetic routes
- Innovation & Intellectual Property (IP) Creation
- Proven ability to move from lab to kilo lab to pilot plant to commercial scale efficiently
- Ensuring technology transfer packages are complete, reproducible, and compliant
Facility
1 R&D facility & 3 Process & Development facilities — 30,000 sq.ft. built-up area
Team
100+ Scientific team along with 20+ PhDs (with associated partners)
Labs
5 synthesis labs with walk-in fume hoods & 4 analytical labs with sophisticated instruments
API Research & Development: Where Science Meets Strategy
- Advanced Synthetic Design: Expertly crafting complex molecules and novel synthetic pathways to drive the next generation of APIs.
- Process Optimization: Enhancing yields and purity profiles through rigorous chemical engineering and innovative methodology.
- Analytical Mastery: Comprehensive characterization and impurity profiling to meet the highest global pharmacopeial standards.
- IP-Driven Innovation: A strategic focus on creating and protecting intellectual property to give our partners a competitive market edge.
CDMO R&D (Development & Manufacturing): Seamless Scale-Up Commercialization
- Scalable Process Design: Developing robust chemical processes engineered for reproducible, large-scale commercial manufacturing.
- Rapid Tech Transfer: Minimizing time-to-market through streamlined, "right-first time" technology transfer.
- Regulatory Compliance: Expert navigation of global regulatory landscapes, ensuring every process is validated and audit-ready.
- Agile Ecosystem: In-house infrastructure provides flexibility to pivot between kilo-lab batches and full-scale production campaigns.
Core Chemistry Activities
- Complex Heterocyclic And Chiral Chemistry
- Hydrogenation And High-Pressure Reactions
- Cross-Coupling (Suzuki-Miyaura, Heck Reaction, Buchwald-Hartwig, Sonogashira, Negishi etc.) And Organometallic Chemistry (Grignard Reaction)
- Halogenation, Nitration, Phosgenation & Phosphorylation
- Cyanation Process
- Carbohydrate Chemistry
Intellectual Property Management
Roles
- Innovation support
- Infringement Screening
- IP-Validation
- FTO-Analysis
- Patent drafting
- Patent Filing
- IP-Alerts
Tools / Databases
- CAS Scifinder
- United States Patent & Trademark Office
- European Patent Office
- WIPO
- Scopus
- PubMed
Talent Pool
- Registered Indian Patent Agent with Organic Chemistry PGs & Ph.Ds.
- Experts in data mining in literature databases and interpretation of techno-legal documents
- 15+ Years of Experienced Resources
Page 5 of 8
5
Manufacturing
Sacred Science of Production — Manufacturing with Precision & Purpose
API / CRAMS Capability – Proven in 20+ APIs & Still Developing
Glochem is on a growth trajectory, with plans to introduce 4–7 new API molecules annually, along with new specialty chemicals, while also exploring opportunities in New Chemical Entities (NCE) with originators.
Approximately 80,000 sq. meters of land is available, and dedicated blocks for CMO activities can be built under a partnership module. Backward integration leads to cost competitiveness, supply reliability, and quality control.
Group of Companies
CHIERON
Complex Generics & Drug Delivery Innovation
DMFs filed: 13 | Under filing (FY 25–26): 6
CEPs filed: 5 | Under filing (FY 25–26): 7
DMFs filed: 13 | Under filing (FY 25–26): 6
CEPs filed: 5 | Under filing (FY 25–26): 7
MAKSONS
Dedicated CDMO unit for specialty chemicals and OLED
A CDMO and dedicated CRAMS site driven by precision, customization, and scalable manufacturing.
A CDMO and dedicated CRAMS site driven by precision, customization, and scalable manufacturing.
Manufacturing Capabilities Detail
CHIERON
- Campus: 90,000 m² with 80,000 m² expansion-ready
- Capacity: 360 KL installed; 200 KL under production
- Blocks: 2 independent production blocks (PB-1A & PB-2)
- Clean rooms: 6 ISO-8 certified clean rooms
- Reactors: 28 SS & GL reactors
- Downstream: 7 centrifuges, 10 filters
- Drying: 10 dryers, 7 size-reduction units
- Sustainability: 15 KL solvent recovery; 100 KL ETP
GLOCHEM INDIA
- Campus: 15,135 m² operational
- Capacity: 96 KL installed (~50 KL under finalization)
- Blocks: 5 independent (PB-1, 2, 4, 5, 6)
- Clean rooms: 3 ISO-8 certified
- Reactors: 46 reactors, diverse configurations
- Downstream: 16 centrifuges, 16 filtration
- Drying: 15 dryers, 12 size-reduction
- Sustainability: 10 KL SRP; 75 KL ETP
MAKSONS
- Campus: 10,300 m² operational
- Capacity: 20.13 KL installed
- Blocks: 1 independent block (PB-1); new block designed for 120 KL
- Reactors: 13 reactors (hazardous chemistry capable)
- Downstream: 4 centrifuges, 2 filtration
- Drying: 1 VBD & 1 RCVD, 1 micropulverizer
- Sustainability: In-process solvent recovery; 13 KL ETP
Particulars
| Particulars | Chieron | Glochem India | Maksons |
|---|---|---|---|
| Total site area | 169,400 m²* | 15,135 m² | 10,300 m² |
| Total capacity | 350 KL | 56 KL | 20.13 KL |
| Block details | 2 blocks (PB1 & PB2) | 5 blocks (PB1,2,4,5,6) | 1 block (PB-1) |
| SRP equipment capacity | 15 KL | 10 KL | – |
| ETP capacity | 100 KL | 75 KL | 13 KL |
| No. of clean rooms | 6 (ISO-8 certified) | 3 (ISO-8 certified) | – |
* An additional 50,000 m² is available for setting up new production blocks.
Equipment Details
| Equipment | Chieron | Glochem India | Maksons |
|---|---|---|---|
| Total reactors | 41 | 46 | 13 |
| Dryers | 10 | 16 | 02 |
| — SSR (Stainless Steel) | 38 | 38 | 10 |
| — GLR (Glass Lined) | 21 | 8 | 03 |
| Size reduction equipment | 07 | 12 | 01 |
Page 6 of 8
6
Sustainability
FIT FOR FUTURE through Sustainable Excellence
Our Approach to Sustainability
At Glochem, sustainability is not a standalone initiative — it is the foundation of how we operate, innovate, and grow. We integrate sustainable practices into every stage of our business, from responsible sourcing and green chemistry to employee well-being and community development.
Our vision is to create long-term value for our stakeholders while safeguarding the environment and communities in which we operate. We believe that sustainable growth stems from ethical decision-making, efficient resource use, and a commitment to health, safety, and transparency.
"We are committed to manufacturing excellence that protects the planet and empowers people."
Sustainability Pillars
Climate Action Leadership
Comprehensive decarbonization strategy aligned with Paris Agreement's 1.5°C scenario. Near-term target by 2035 and Net Zero commitment by 2050, validated by Science Based Targets initiative (SBTi).
Global Safety Excellence
ISO 45001 certified sites with zero fatal accidents record. Continuous safety awareness programs and behavioral safety training across all manufacturing locations.
Proud Member – British Safety Council
Recognized with the prestigious International Safety Award (Merit 2026) for demonstrating exemplary commitment to health, safety, and workplace well-being standards.
Industry Collaboration
Active participation in the Pharmaceutical Supply Chain Initiative (PSCI), adopting sectoral sustainability programs to drive industry-wide environmental and social progress.
Sustainability Governance Framework
At Glochem, sustainability is a shared responsibility led from the top and practiced across every function. Our governance structure ensures that environmental, social, and ethical considerations are integrated into our business strategy, operations, and decision-making processes.
Sustainability oversight begins with the Board of Directors, which reviews sustainability performance and policy updates periodically. The Managing Director provides strategic direction, while the EHS & Sustainability Committee drives implementation across sites and monitors progress against company-wide targets.
"Leadership accountability is at the heart of our sustainability journey."
Our Sustainability Impact
20,000 KL
Water reused in FY-25
15.06%
Reduction in Scope 1 emissions
2,812,930 KWh
Renewable energy consumption
Our Approach for Low Carbon Business Model
Internal Initiatives
- Rooftop Solar
- Energy Efficiency Projects
- Energy Management System (EnMS)
- Product Carbon Footprint & Emission Hotspot Identification
External Initiatives
- Renewable Energy Access
- Supply Chain GHG Reduction
Page 7 of 8
7
ESG – Environmental, Social & Governance
FIT FOR FUTURE through Sustainable Excellence
ESG Profile
Your trusted API & CDMO partner for complex chemistry, reliable scale-up, and sustainable growth
- EcoVadis Gold & Silver Rated Sites
- CDP B Rating (2025) With Zero Liquid Discharge Operations
- 2 MW Solar Power Utilization
- ISO 9001, ISO 14001, OHSAS 18001 Certified
- Recipient Of The Golden Peacock Award For EHS Excellence
IOD Event: First Launch of Sustainability Reports of Glochem
Glochem marked a significant milestone by launching its inaugural Sustainability Report at the IOD (Institute of Directors) event, reinforcing its commitment to transparent environmental and social governance.
Recognitions
PSCIEcovadisCDPScience Based TargetsGRIBritish Safety CouncilUN Global Compact
Our Approach for Low Carbon Business Model
Internal
Solar rooftop, energy efficiency projects, energy management system and product carbon footprint to understand hot spots
External (Access)
Access To Renewable Energy
External (Supply Chain)
Supply Chain GHG Reductions
Key Actions to Enhance OHS Culture & Safety Performance
- Management Walk Through Once/Month
- Implement SBO App For Safety Reporting Culture & Sense Of Employee Involvement
- Safety Part Of Performance Management
- BBS Training
- Bonus/Incentive Linked With Plant Safety Performance
- Endorsement Of National & International Safety Initiatives Like British Safety Council
- Safety Awards (Internal – Best Department)
Certifications
We maintain compliance with multiple international standards to continuously improve our processes, minimize risks, and reduce environmental impact. Each certification represents an independent assurance of Chieron's robust governance and sustainability practices.
Our Upcoming Milestones
- Targeting EcoVadis Platinum Award (2026–27)
- Participating In ICC, Golden Peacock, And CII Awards
- Awarded British Safety Council International Safety Award
- Pursuing Green Lab Certification For R&D & Process Labs
- Implementing DuPont Engagement Program To Enhance Safety & Operational Excellence
Page 8 of 8
8
Get In Touch
Connect with our Global Business, CDMO Partnerships, and Regulatory Teams
Communication Channels
We welcome inquiries regarding commercial API supply, custom synthesis, scale-up, and regulatory filings.
📧 Email – Business Development & Sales
sagar.mule@glochemindia.com
📧 Email – Commercial & Partnership
suresh.chintha@glochemindia.com
📧 Email – Chieron CDMO & APIs
zahra.s@chieron.com
📧 Email – General Inquiries
info@glochemindia.com
📞 Phone Support
+91-40-44665065 | Mon – Fri: 9:30 AM – 6:30 PM IST
🏢 Corporate Headquarters
3rd Floor, NCC Building, Durgam Cheruvu Road, Hi Tech City, Madhapur, Hyderabad, Telangana, India
Our Office Network
Strategically positioned across India's leading pharmaceutical hubs
Hyderabad (Corporate Office)
3rd Floor, NCC Building, Durgam Cheruvu Road, Hi Tech City, Madhapur, Hyderabad, Telangana, India
Hyderabad (Plant IDA Jeedimetla)
Plot No. 34/B, 34/C, 35, Phase-I, IDA, Jeedimetla, Hyderabad, Telangana - 500 055, India
Mumbai Office
114, 1st Floor, Neo Corporate Plaza, Kanchpada, Ramchandra Lane Extn., Malad (West), Mumbai - 400 064, India
Bangalore Office
3rd Floor, SLN arcade, 7th main, 80ft road, 1st block, HRBR layout, Kalyan Nagar, Bangalore - 560 043, India
Ahmedabad R&D Facility
Westgate Business Bay, B Block, 14th Floor, Corporate Road, Makarba, Ahmedabad - 380 051, Gujarat, India
Glochem Industries · An API & CDMO Company
Safety First · Quality Always · Productivity Daily